Cargando…
Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma
Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three s...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459593/ https://www.ncbi.nlm.nih.gov/pubmed/36157698 http://dx.doi.org/10.1159/000526077 |
_version_ | 1784786548167802880 |
---|---|
author | Takahashi, Satoru Endo, Masashi Fukuda, Yukiko Ogawa, Kazunari Nakamura, Michiko Okada, Kohei Kawahara, Masahiro Akahane, Keiko Nagatomo, Takafumi Onaga, Ryutaro Nishino, Hiroshi Mori, Harushi Shirai, Katsuyuki |
author_facet | Takahashi, Satoru Endo, Masashi Fukuda, Yukiko Ogawa, Kazunari Nakamura, Michiko Okada, Kohei Kawahara, Masahiro Akahane, Keiko Nagatomo, Takafumi Onaga, Ryutaro Nishino, Hiroshi Mori, Harushi Shirai, Katsuyuki |
author_sort | Takahashi, Satoru |
collection | PubMed |
description | Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three systems: vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor inhibitions. It was initially developed as an anticancer drug for non-small-cell lung carcinoma; however, it was also found to inhibit the proliferation of fibroblasts associated with chronic inflammation in the lungs. Therefore, it is being more widely used to treat idiopathic pulmonary fibrosis, a benign disease, than as an antineoplastic agent. Several studies have reported adverse events associated with the concurrent use of MKIs with surgery or radiotherapy. Specifically, there has been a report cautioning against delayed wound healing associated with the use of nintedanib in patients undergoing surgery. However, there is no specific mention of its concurrent use during irradiation. We describe a case of a 72-year-old man with severely delayed recovery from radiation mucositis when nintedanib was being administered for benign disease. |
format | Online Article Text |
id | pubmed-9459593 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-94595932022-09-23 Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma Takahashi, Satoru Endo, Masashi Fukuda, Yukiko Ogawa, Kazunari Nakamura, Michiko Okada, Kohei Kawahara, Masahiro Akahane, Keiko Nagatomo, Takafumi Onaga, Ryutaro Nishino, Hiroshi Mori, Harushi Shirai, Katsuyuki Case Rep Oncol Case Report Since the launch of imatinib in 2001, tyrosine kinase inhibitors are being used in chemotherapy for a wide range of malignant tumors. Drugs that inactivate multiple molecular mechanisms are called multikinase inhibitors (MKIs). Nintedanib is a type of MKI that inhibits downstream cascades in three systems: vascular endothelial growth factor receptor, fibroblast growth factor receptor, and platelet-derived growth factor receptor inhibitions. It was initially developed as an anticancer drug for non-small-cell lung carcinoma; however, it was also found to inhibit the proliferation of fibroblasts associated with chronic inflammation in the lungs. Therefore, it is being more widely used to treat idiopathic pulmonary fibrosis, a benign disease, than as an antineoplastic agent. Several studies have reported adverse events associated with the concurrent use of MKIs with surgery or radiotherapy. Specifically, there has been a report cautioning against delayed wound healing associated with the use of nintedanib in patients undergoing surgery. However, there is no specific mention of its concurrent use during irradiation. We describe a case of a 72-year-old man with severely delayed recovery from radiation mucositis when nintedanib was being administered for benign disease. S. Karger AG 2022-08-30 /pmc/articles/PMC9459593/ /pubmed/36157698 http://dx.doi.org/10.1159/000526077 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Takahashi, Satoru Endo, Masashi Fukuda, Yukiko Ogawa, Kazunari Nakamura, Michiko Okada, Kohei Kawahara, Masahiro Akahane, Keiko Nagatomo, Takafumi Onaga, Ryutaro Nishino, Hiroshi Mori, Harushi Shirai, Katsuyuki Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title | Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title_full | Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title_fullStr | Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title_full_unstemmed | Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title_short | Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma |
title_sort | nintedanib-induced delayed mucosal healing after adjuvant radiation in a case of oropharyngeal carcinoma |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459593/ https://www.ncbi.nlm.nih.gov/pubmed/36157698 http://dx.doi.org/10.1159/000526077 |
work_keys_str_mv | AT takahashisatoru nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT endomasashi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT fukudayukiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT ogawakazunari nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT nakamuramichiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT okadakohei nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT kawaharamasahiro nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT akahanekeiko nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT nagatomotakafumi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT onagaryutaro nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT nishinohiroshi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT moriharushi nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma AT shiraikatsuyuki nintedanibinduceddelayedmucosalhealingafteradjuvantradiationinacaseoforopharyngealcarcinoma |